Associate Professor; Director of Radiation Biology Research & Education
Radiation Oncology
Baylor College of Medicine
Houston, Texas, United States
Assistant Professor
Houston Methodist Research Institute
Postdoctoral Scientist
Cardiovascular Medicine
Stanford University
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas, United States


PhD from University of Cape Town

Honors & Awards

Fellow of the American Heart Association

Professional Statement

Regulation of the nitric oxide synthase (NOS) pathway using small molecules is a major strategy we employ in my laboratory to translate basic research insights into useful therapy for cardiovascular and pulmonary diseases. Recently, we applied high throughput screening (HTS) technology to discover small molecules that directly regulate this pathway. Intriguingly, we discovered that proton pump inhibitors (PPIs; a class of FDA-approved drug developed to treat gastric acidity) directly modulate the NOS pathway and regulate many of the downstream processes associated with overly active NOS including tissue inflammation and fibrosis.

More recently, we demonstrated that PPIs suppress lung inflammation and fibrosis in an experimental model of acute lung injury in part by regulating the transcription of inducible NOS (iNOS) and several classic pro-inflammatory cytokines.

Currently, we have ongoing cardiovascular and pulmonary projects that leverage our strength in pharmacology:

Cardiovascular: Our projects include modulation of the vascular endothelial system using small molecules and microRNA to treat cardiovascular disease including atherosclerosis.

Pulmonary: We are working towards developing stand-alone and combinatorial therapy to modulate lung inflammation and fibrosis that results from chemical (e.g. bleomycin) or ionizing radiation.

Selected Publications


American Thoracic Society
American Heart Association


DDAH As a Novel Target in Pulmonary Fibrosis
Grant funding from NIH (NHLBI)

Intellectual Property

Dimethylarginine Dimethylaminohydrolase Inhibitors and Methods of Use Thereof
Use of small molecules including proton pump inhibitors (PPIs) to modulate lung remodeling.